中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.031 seconds)

筛选除外

    Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
    3.
    发明申请
    Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass 审中-公开
    使用左西孟旦治疗需要心肺旁路的心脏手术患者的左心室收缩功能障碍

    公开(公告)号：US20150374689A1

    公开(公告)日：2015-12-31

    申请号：US14751476

    申请日：2015-06-26

    Applicant: TENAX Therapeutics, Inc.

    Inventor： John Kelley ,  Doug Randall ,  Douglas Hay

    IPC: A61K31/50

    CPC classification number: A61K31/50

    Abstract: Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min.

    Abstract translation: （i）减少接受心脏手术的人类患者的发病率和/或死亡率的方法; （ii）在接受心脏手术的人类患者中预防或降低LCOS发展的风险; 或（iii）减少在接受心脏手术的人类患者中的一个或多个术后不良事件的风险，强度或发生的风险。 所述方法可以包括（a）给患者左西孟旦施用约1小时的第一时期，其中在第一时期开始给予左西孟旦;（i）在皮肤切开心脏手术之前，和（ii） 约0.2μg/ kg / min的输注剂量; 和（b）向患者左西孟旦施用约23小时的第二个时期，其中在约0.1μg/ kg / min的输注剂量下开始第二次给予左西孟旦。

    Pharmaceutical compositions for subcutaneous administration of levosimendan
    7.
    发明授权
    Pharmaceutical compositions for subcutaneous administration of levosimendan 有权

    公开(公告)号：US11213524B2

    公开(公告)日：2022-01-04

    申请号：US16544098

    申请日：2019-08-19

    Applicant: Tenax Therapeutics, Inc.

    Inventor： Doug Randall ,  Douglas Hay ,  Nancy J. M. Hecox

    IPC: A61K31/50 ,  A61K47/40 ,  A61K9/00 ,  A61K9/19

    Abstract: A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

    Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan
    9.
    发明申请
    Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan 审中-公开

    公开(公告)号：US20200330463A1

    公开(公告)日：2020-10-22

    申请号：US16544098

    申请日：2019-08-19

    Applicant: Tenax Therapeutics, Inc.

    Inventor： Doug Randall ,  Douglas Hay ,  Nancy J.M. Hecox

    IPC: A61K31/50 ,  A61K47/40

    Abstract: A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

Patent Agency Ranking